AVBP logo

AVBP ArriVent BioPharma Inc.

$14.80
$13.37
(46.98%)
Today
Closed $15.09
$0.29
(1.92%)
After Hours
87

Extremely Bullish Sentiment

How do you feel about AVBP?

Loading...

This is an ad slot. Start your free Edge trial and you won't see any ads for 30 days.

Ad free · Full sentiment data · Expanded watchers · Advanced search · No credit card required.

Advertisement|

SpudZone
$AVBP Back in for scalp #2 LONG for power hour. Nice bid action today off lows, buyers showed up - maybe high risk overnight if strong close
1
Nitish_mahajan2
$AVBP This will recover a bit. They have a lot of things in pipeline with $373 milion cash where it is trading after this drop
2
JFais
$AVBP (NP) Today's biotech gut punch, down ~60% on failed phase 3 in 1L EGFR exon20 NSCLC $200M EV = perhaps a "bait & switch" opportunity when the dust clears Focus shifts to ADC programs (CDH17 in GI cancers & MUC16/NaPi2b in ovarian & endometrial) *Both via China deals
2
Nitish_mahajan2
$AVBP Cash and investments: $373.1 million as of June 30, 2026.. It is trading at cash value market cap after this drop. WAY UNDERVALUED
1
KryptonResearch14
$AVBP ArriVent's firmonertinib missed its Phase 3 in first-line lung cancer today. Shares are down 54% to about 13, on pace for the stock's worst single-day drop on record (Dow Jones). FURVENT tested the once-daily pill against chemo in previously untreated advanced NSCLC with EGFR exon 20 insertions. The higher dose gave 11 months of median progression-free survival vs 9.5 for chemo; the lower dose came in at 8.4 months, under chemo. Tumors shrank in about 60% of patients on the higher dose vs 33% on chemo. CEO Bing Yao said the results were "consistent" with earlier studies but did not show a meaningful improvement over chemo. One level down: this is not the whole franchise. The drug is already approved in China for second-line exon 20 disease (partner Allist, February), and the PACC-mutation program posted a 16.0-month median PFS in Phase 1b. Its pivotal ALPACCA Phase 3 is now enrolling. The first-line exon 20 thesis is done. PACC is the next checkpoint.
mikesterz7
$AVBP 🚨🚨🚨 ArriVent BioPharma’s experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial.
StocktwitsNews
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’ $AVBP $XBI https://stocktwits.com/news/equity/markets/avbp-stock-crashes-to-all-time-low-after-lung-cancer-trial-setback/cZDtOaDRBlO
MikeBob15
$AVBP Can someone please tell me how a stock with a billion and a half market cap and five hundred thousand shares , daily volume has a spread of about .20???